VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Vertex Pharmaceuticals: "This company is doing the lord's work...I think it should be bought." CME Group: "It is one of the most consistent, great companies...It is a strong buy." T. Rowe Price ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive ...

As of October 28, 2024, Vertex Pharmaceuticals Incorporated had a $123.0 billion market capitalization, putting it in the 98th percentile of companies in the Biotechnology industry. Vertex ...

That includes, apparently, launching three-pointers with his heels on the logo. Watch video of Wembanyama ripping a ridiculously deep pull-up three here: Wembanyama is obviously on his way to ...

At the heart of this biotech boom lies Vertex Pharmaceuticals, a trailblazer that has played a pivotal role in transforming medical landscapes and reshaping patient lives. From groundbreaking ...

pharmaceuticals, investment, and patient advocacy. A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that makers and marketers of prescription opioid ...

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $515.00. The company’s shares closed yesterday at ...

Scotiabank has recently initiated Vertex Pharmaceuticals Incorporated (VRTX) stock to Sector Perform rating, as announced on October 16, 2024, according to Finviz. Earlier, on October 10, 2024, ...